HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Valluvan Jeevanandam V. Paul Addonizio Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Korn, R. L. Articles by Addonizio, V. P. Search for Related Content PubMed PubMed Citation Articles by Korn, R. L. Articles by Addonizio, V. P.

J Thorac Cardiovasc Surg 1996;111:1073-1084
© 1996 Mosby, Inc.

CARDIOPULMONARY BYPASS, MYOCARDIAL MANAGEMENT, AND SUPPORT TECHNIQUES

THE EFFECTS OF CARMEDA BIOACTIVE SURFACE ON HUMAN BLOOD COMPONENTS DURING SIMULATED EXTRACORPOREAL CIRCULATION

This work was supported in part by funds from Medtronics Cardiopulmonary, Anaheim, Calif.

Received for publication Dec. 22, 1994 Accepted for publication June 27, 1995. Address for reprints: V. Paul Addonizio, MD, Professor and Chief, Cardiac and Thoracic Surgery, Department of Surgery, Temple University Health Sciences Center, 300 Parkinson Pavilion, Broad & Ontario Streets, Philadelphia, PA 19140.

Abstract

Postoperative morbidity after cardiopulmonary bypass most commonly manifests as bleeding diatheses or pulmonary dysfunction. The pathophysiology has been attributed to the activation of cellular and humoral components of blood after contact with an artificial surface. Development of a surface that would be nonthrombogenic and also would constitute a less potent inflammatory stimulus would therefore be beneficial. In the following experiments, we evaluated the heparin-bonded Carmeda Bioactive Surface (Medtronics Cardiopulmonary, Anaheim, Calif.) in an in vitro model of extracorporeal circulation at standard-dose heparin (5 U/ml), to examine the effects of the surface treatment on activation of blood elements, and at reduced-dose heparin (1 U/ml), to determine whether surface-bound heparin would serve as an effective anticoagulant. During the initial recirculation period, platelet counts in the Carmeda (n = 12) circuits were preserved at both doses of heparin and compared with control values (n = 12): At 5 U/ml, control 36% ± 4% (mean ± standard error of the mean) versus Carmeda 81% ± 5%; at 1 U/ml, 43% ± 3% versus 61% ± 10%, expressed as a percent of baseline at 30 minutes, p < 0.05. Furthermore, plasma levels of platelet factor 4 andß-thromboglobulin were significantly reduced in the Carmeda circuits throughout the experiment: At heparin 5 U/ml, 2500 ± 340 ng/ml versus 604 ± 191 ng/ml; at 1 U/ml, 2933 ± 275 ng/ml versus 577 ± 164 ng/ml of platelet factor 4 at 2 hours (p < 0.05). The pattern ofß-thromboglobulin release was similar, with effects more pronounced at the lower dose of heparin. Surface modification also reduced leukocyte depletion (p < 0.05) and release of elastase at both concentrations of heparin (5 U/ml, 0.72 ± 0.29 ng/ml versus 0.33 ± 0.23 ng/ml; 1 U/ml, 0.85 ± 0.08 ng/ml versus 0.20 ± 0.05 ng/ml, at 2 hours, p < 0.05). Moreover, as heparin concentration was reduced, Carmeda surface treatment significantly decreased generation of C3a des Arg (1 U/ml, 14,410 ± 3558 ng/ml versus 3053 ± 1039 ng/ml at 2 hours, p < 0.05). Although heparin bonding was originally intended to obviate the need for systemic heparinization, Carmeda treatment did not reduce fibrinopeptide A generation at the lower dose of heparin. In summary, Carmeda treatment failed to exhibit anticoagulant efficacy in this model; however, the data suggest that surface modification may have a role in ameliorating the typical inflammatory response initiated by blood contact with an artificial surface. (J THORACCARDIOVASCSURG1996;111:1073-84)

This article has been cited by other articles:

				K. T. Lappegard, J. Riesenfeld, O.-L. Brekke, G. Bergseth, J. D. Lambris, and T. E. Mollnes Differential Effect of Heparin Coating and Complement Inhibition on Artificial Surface-Induced Eicosanoid Production Ann. Thorac. Surg., March 1, 2005; 79(3): 917 - 923. [Abstract] [Full Text] [PDF]

				J. Butler, E. W. Murithi, V. L. Pathi, K. J.D. MacArthur, and G. A. Berg Duroflo II heparin bonding does not attenuate cytokine release or improve pulmonary function Ann. Thorac. Surg., July 1, 2002; 74(1): 139 - 142. [Abstract] [Full Text] [PDF]

				L.-C. Hsu Heparin-coated cardiopulmonary bypass circuits: current status Perfusion, September 1, 2001; 16(5): 417 - 428. [Abstract] [PDF]

				T. Nakajima, K. Kawazoe, K. Ishibashi, Y. Kubota, T. Sasaki, H. Izumoto, and T. Nitatori Reduction of heparin dose is not beneficial to platelet function Ann. Thorac. Surg., July 1, 2000; 70(1): 186 - 190. [Abstract] [Full Text] [PDF]

				E. A. Grossi, K. Kallenbach, S. Chau, C. C. Derivaux, M. G. Aguinaga, B. M. Steinberg, D. Kim, S. Iyer, M. Tayyarah, M. Artman, et al. Impact of heparin bonding on pediatric cardiopulmonary bypass: a prospective randomized study Ann. Thorac. Surg., July 1, 2000; 70(1): 191 - 196. [Abstract] [Full Text] [PDF]

				H. P. Wendel and G. Ziemer Coating-techniques to improve the hemocompatibility of artificial devices used for extracorporeal circulation Eur. J. Cardiothorac. Surg., September 1, 1999; 16(3): 342 - 350. [Abstract] [Full Text] [PDF]

				Y. J. Gu, P. W. Boonstra, and W. van Oeveren Effect of normoxic cardiopulmonary bypass on leukocyte elastase release J. Thorac. Cardiovasc. Surg., May 1, 1999; 117(5): 1045 - 1046. [Full Text]

				C B. Mahoney Heparin-bonded circuits: clinical outcomes and costs Perfusion, May 1, 1998; 13(3): 192 - 204. [Abstract] [PDF]

				R. C. Hill, S. Bannan, and P. G. Martin Low heparinization and heparin-bonded circuits. Ann. Thorac. Surg., October 1, 1997; 64(4): 1221 - 1222. [Full Text]

				S. Bannan, A. Danby, D. Cowan, S. Ashraf, and P. G. Martin Low Heparinization With Heparin-Bonded Bypass Circuits: Is It a Safe Strategy? Ann. Thorac. Surg., March 1, 1997; 63(3): 663 - 668. [Abstract] [Full Text]